Cargando…
Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates
Tuberculosis (TB) remains a serious public health threat around the world. An effective vaccine is urgently required for cost-effective, long-term control of TB. However, the only licensed vaccine Bacillus Calmette-Guerin (BCG) is limited to prevent TB for its highly variable efficacy. Substantial p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652786/ https://www.ncbi.nlm.nih.gov/pubmed/38022657 http://dx.doi.org/10.3389/fimmu.2023.1238649 |
_version_ | 1785136290378809344 |
---|---|
author | Zhou, Fangbin Zhang, Dongmei |
author_facet | Zhou, Fangbin Zhang, Dongmei |
author_sort | Zhou, Fangbin |
collection | PubMed |
description | Tuberculosis (TB) remains a serious public health threat around the world. An effective vaccine is urgently required for cost-effective, long-term control of TB. However, the only licensed vaccine Bacillus Calmette-Guerin (BCG) is limited to prevent TB for its highly variable efficacy. Substantial progress has been made in research and development (R&D) of TB vaccines in the past decades, and a dozen vaccine candidates, including live attenuated mycobacterial vaccines, killed mycobacterial vaccines, adjuvanted subunit vaccines, viral vector vaccines, and messenger RNA (mRNA) vaccines were developed in clinical trials to date. Nevertheless, many challenges to the successful authorization for the use and deployment of an effective tuberculosis vaccine remain. Therefore, it is still necessary and urgent to continue exploring new vaccine construction approaches. Virus-like particles (VLPs) present excellent prospects in the field of vaccine development because of their helpful immunological features such as being safe templates without containing viral nucleic acid, repetitive surface geometry, conformational epitopes similar to natural viruses, and enhancing both innate and adaptive immune responses. The marketization process of VLP vaccines has never stopped despite VLP vaccines face several shortcomings such as their complex and slow development process and high production cost, and several VLP-based vaccines, including vaccines against Human papillomavirus (HPV), Hepatitis B Virus (HBV) and malaria, are successfully licensed for use at the market. In this review, we provide an update on the current progress regarding the development of TB vaccines in clinical trials and seek to give an overview of VLP-based TB vaccine candidates. |
format | Online Article Text |
id | pubmed-10652786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106527862023-01-01 Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates Zhou, Fangbin Zhang, Dongmei Front Immunol Immunology Tuberculosis (TB) remains a serious public health threat around the world. An effective vaccine is urgently required for cost-effective, long-term control of TB. However, the only licensed vaccine Bacillus Calmette-Guerin (BCG) is limited to prevent TB for its highly variable efficacy. Substantial progress has been made in research and development (R&D) of TB vaccines in the past decades, and a dozen vaccine candidates, including live attenuated mycobacterial vaccines, killed mycobacterial vaccines, adjuvanted subunit vaccines, viral vector vaccines, and messenger RNA (mRNA) vaccines were developed in clinical trials to date. Nevertheless, many challenges to the successful authorization for the use and deployment of an effective tuberculosis vaccine remain. Therefore, it is still necessary and urgent to continue exploring new vaccine construction approaches. Virus-like particles (VLPs) present excellent prospects in the field of vaccine development because of their helpful immunological features such as being safe templates without containing viral nucleic acid, repetitive surface geometry, conformational epitopes similar to natural viruses, and enhancing both innate and adaptive immune responses. The marketization process of VLP vaccines has never stopped despite VLP vaccines face several shortcomings such as their complex and slow development process and high production cost, and several VLP-based vaccines, including vaccines against Human papillomavirus (HPV), Hepatitis B Virus (HBV) and malaria, are successfully licensed for use at the market. In this review, we provide an update on the current progress regarding the development of TB vaccines in clinical trials and seek to give an overview of VLP-based TB vaccine candidates. Frontiers Media S.A. 2023-11-02 /pmc/articles/PMC10652786/ /pubmed/38022657 http://dx.doi.org/10.3389/fimmu.2023.1238649 Text en Copyright © 2023 Zhou and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhou, Fangbin Zhang, Dongmei Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
title | Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
title_full | Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
title_fullStr | Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
title_full_unstemmed | Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
title_short | Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
title_sort | recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652786/ https://www.ncbi.nlm.nih.gov/pubmed/38022657 http://dx.doi.org/10.3389/fimmu.2023.1238649 |
work_keys_str_mv | AT zhoufangbin recentadvanceinthedevelopmentoftuberculosisvaccinesinclinicaltrialsandviruslikeparticlebasedvaccinecandidates AT zhangdongmei recentadvanceinthedevelopmentoftuberculosisvaccinesinclinicaltrialsandviruslikeparticlebasedvaccinecandidates |